{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T11:27:44Z","timestamp":1769081264967,"version":"3.49.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":638,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"British Heart Foundation Centre of Research Excellence","award":["RE\/18\/6\/34217"],"award-info":[{"award-number":["RE\/18\/6\/34217"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Approximately half of patients with heart failure and a reduced ejection fraction (HeFREF) are discharged from hospital on triple therapy [angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), beta-blockers (BBs), and mineralocorticoid receptor antagonists (MRAs)]. We investigated what proportion of patients are on optimal doses prior to discharge and how many might be eligible for initiation of sacubitril\u2013valsartan or sodium-glucose co-transporter-2 inhibitors (SGLT2Is).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Between 2012 and 2017, 1277 patients admitted with suspected heart failure were enrolled at a single hospital serving a local community around Kingston upon Hull, UK. Eligibility for sacubitril\u2013valsartan or SGLT2I was based on entry criteria for the PIONEER-HF, DAPA-HF, and EMPEROR-Reduced trials. Four hundred fifty-five patients had HeFREF with complete data on renal function, heart rate, and systolic blood pressure (SBP) prior to discharge. Eighty-three per cent of patients were taking an ACE-I or ARB, 85% a BB, and 63% an MRA at discharge. More than 60% of patients were eligible for sacubitril\u2013valsartan and &amp;gt;70% for SGLT2I. Among those not already receiving a prescription, 37%, 28%, and 49% were eligible to start ACE-I or ARB, BB, and MRA, respectively. Low SBP (\u2264105 mmHg) was the most frequent explanation for failure to initiate or up-titrate therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Most patients admitted for heart failure are eligible for initiation of life-prolonging medications prior to discharge. A hospital admission may be a common missed opportunity to improve treatment for patients with HeFREF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14638","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:25:35Z","timestamp":1705451135000},"page":"950-961","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Medicines Optimization Prior to Discharge in Patients Admitted to Hospital with Heart Failure"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4339-3062","authenticated-orcid":false,"given":"Joseph J.","family":"Cuthbert","sequence":"first","affiliation":[{"name":"Clinical Sciences Centre, Hull York Medical School, University of Hull , Kingston upon Hull, East Riding of Yorkshire ,","place":["UK"]},{"name":"Department of Cardiology, Hull University Teaching Hospital Trust, Castle Hill Hospital , Kingston upon Hull, East Riding of Yorkshire ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver I.","family":"Brown","sequence":"additional","affiliation":[{"name":"Clinical Sciences Centre, Hull York Medical School, University of Hull , Kingston upon Hull, East Riding of Yorkshire ,","place":["UK"]},{"name":"Department of Cardiology, Hull University Teaching Hospital Trust, Castle Hill Hospital , Kingston upon Hull, East Riding of Yorkshire ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierpaolo","family":"Pellicori","sequence":"additional","affiliation":[{"name":"British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Health, University of Glasgow , 126 University Place, Glasgow, Glasgow, G12 8TA, Lanarkshire ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Dobbs","sequence":"additional","affiliation":[{"name":"Clinical Sciences Centre, Hull York Medical School, University of Hull , Kingston upon Hull, East Riding of Yorkshire ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne","family":"Bulemfu","sequence":"additional","affiliation":[{"name":"Clinical Sciences Centre, Hull York Medical School, University of Hull , Kingston upon Hull, East Riding of Yorkshire ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed","family":"Kazmi","sequence":"additional","affiliation":[{"name":"Clinical Sciences Centre, Hull York Medical School, University of Hull , Kingston upon Hull, East Riding of Yorkshire ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioanna","family":"Sokoreli","sequence":"additional","affiliation":[{"name":"Remote Patient Management and Chronic Care, Philips Research Eindhoven , Eindhoven ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffan C.","family":"Pauws","sequence":"additional","affiliation":[{"name":"Remote Patient Management and Chronic Care, Philips Research Eindhoven , Eindhoven ,","place":["The Netherlands"]},{"name":"Department of Communication and Cognition, Tilburg University , Tilburg ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarno M.","family":"Riistama","sequence":"additional","affiliation":[{"name":"Philips Image Guided Therapy Devices , Best ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.F.","family":"Cleland","sequence":"additional","affiliation":[{"name":"British Heart Foundation Centre of Research Excellence, School of Cardiovascular and Metabolic Health, University of Glasgow , 126 University Place, Glasgow, Glasgow, G12 8TA, Lanarkshire ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew L.","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hull University Teaching Hospital Trust, Castle Hill Hospital , Kingston upon Hull, East Riding of Yorkshire ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"2026012113152574700_ehf214638-bib-0001","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: A comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"key":"2026012113152574700_ehf214638-bib-0002","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012113152574700_ehf214638-bib-0003","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jamacardio.2020.7585","article-title":"Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction","volume":"6","author":"Berg","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026012113152574700_ehf214638-bib-0004","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/j.amjmed.2019.06.053","article-title":"Early effects of starting doses of enalapril in patients with chronic heart failure in the SOLVD treatment trial","volume":"133","author":"Lam","year":"2020","journal-title":"Am J Med"},{"key":"2026012113152574700_ehf214638-bib-0005","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/ejhf.2149","article-title":"Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction","volume":"23","author":"Packer","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012113152574700_ehf214638-bib-0006","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012113152574700_ehf214638-bib-0007","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jamacardio.2021.0496","article-title":"Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure-optimizing therapy with the need for speed","volume":"6","author":"Greene","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026012113152574700_ehf214638-bib-0008","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1002\/ejhf.2311","article-title":"Simultaneous or rapid sequence initiation of medical therapies for heart failure: Seeking to avoid the case of \u2018too little, too late\u2019","volume":"23","author":"Khan","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012113152574700_ehf214638-bib-0009","volume-title":"The National Heart Failure Audit Summary Report 2018\u20132019","author":"National Institute for Cardiovascular Outcomes Research","year":"2019"},{"key":"2026012113152574700_ehf214638-bib-0010","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10741-021-10135-4","article-title":"Polypharmacy definition and prevalence in heart failure: A systematic review","volume":"27","author":"Beezer","year":"2022","journal-title":"Heart Fail Rev"},{"key":"2026012113152574700_ehf214638-bib-0011","volume-title":"Care of dying adults in the last days of life NICE Guideline NG31","author":"National Institute for Health and Care Excellence"},{"key":"2026012113152574700_ehf214638-bib-0012","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jchf.2013.04.004","article-title":"Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: Results of the PRAISE-2 study (Prospective Randomized Amlodipine Survival Evaluation 2)","volume":"1","author":"Packer","year":"2013","journal-title":"JACC Heart Fail"},{"key":"2026012113152574700_ehf214638-bib-0013","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"2026012113152574700_ehf214638-bib-0014","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1001\/jama.2017.5427","article-title":"Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: The IRONOUT HF randomized clinical trial","volume":"317","author":"Lewis","year":"2017","journal-title":"JAMA"},{"key":"2026012113152574700_ehf214638-bib-0015","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1161\/CIR.0000000000000426","article-title":"Drugs that may cause or exacerbate heart failure: A scientific statement from the American Heart Association","volume":"134","author":"Page","year":"2016","journal-title":"Circulation"},{"key":"2026012113152574700_ehf214638-bib-0016","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012113152574700_ehf214638-bib-0017","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012113152574700_ehf214638-bib-0018","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012113152574700_ehf214638-bib-0019","volume-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Supplementary Data","author":"European Heart Journal. ESC Scientific Document Group"},{"key":"2026012113152574700_ehf214638-bib-0020","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"key":"2026012113152574700_ehf214638-bib-0021","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: Primary results of the randomised TRANSITION study","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012113152574700_ehf214638-bib-0022","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jchf.2020.06.008","article-title":"Efficacy and safety of sacubitril\/valsartan by dose level achieved in the PIONEER-HF trial","volume":"8","author":"Berg","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026012113152574700_ehf214638-bib-0023","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012113152574700_ehf214638-bib-0024","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/j.jacc.2021.08.064","article-title":"In-hospital initiation of sodium-glucose cotransporter-2 inhibitors for heart failure with reduced ejection fraction","volume":"78","author":"Rao","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026012113152574700_ehf214638-bib-0025","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/ejhf.2137","article-title":"Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: Rationale for and design of the EMPULSE trial","volume":"23","author":"Tromp","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012113152574700_ehf214638-bib-0026","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"key":"2026012113152574700_ehf214638-bib-0027","volume-title":"Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction [TA388]","author":"National Institute of Health and Care Excellence","year":"2016"},{"key":"2026012113152574700_ehf214638-bib-0028","volume-title":"Dapagliflozin for treating chronic heart failure with reduced ejection fraction. Technology appraisal guidance [TA679]","author":"National Institute of Health and Care Excellence","year":"2021"},{"key":"2026012113152574700_ehf214638-bib-0029","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/ejhf.2484","article-title":"Heart failure quality of care and in-hospital outcomes during the COVID-19 pandemic findings from the Get With The Guidelines-Heart Failure registry","volume":"24","author":"Keshvani","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012113152574700_ehf214638-bib-0030","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1002\/ejhf.2431","article-title":"Regional differences in precipitating factors of hospitalization for acute heart failure: Insights from the REPORT-HF registry","volume":"24","author":"Tromp","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012113152574700_ehf214638-bib-0031","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-029667","article-title":"Readmission and processes of care across weekend and weekday hospitalisation for acute myocardial infarction, heart failure or stroke: An observational study of the National Readmission Database","volume":"9","author":"Martin","year":"2019","journal-title":"BMJ Open"},{"key":"2026012113152574700_ehf214638-bib-0032","first-page":"1","article-title":"Increasing the heart failure nursing workforce: Recommendations by the British Society for Heart Failure Nurse Forum","volume":"14","author":"Masters","year":"2019","journal-title":"Br J Card Nurs"},{"key":"2026012113152574700_ehf214638-bib-0033","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1161\/CIRCULATIONAHA.106.669101","article-title":"Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes","volume":"116","author":"Gislason","year":"2007","journal-title":"Circulation"},{"key":"2026012113152574700_ehf214638-bib-0034","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s10741-020-09979-z","article-title":"Clinical inertia in the treatment of heart failure: A major issue to tackle","volume":"26","author":"Verhestraeten","year":"2021","journal-title":"Heart Fail Rev"},{"key":"2026012113152574700_ehf214638-bib-0035","volume-title":"National Cost Collection for the NHS. National Schedule of NHS Costs","author":"National Health Service"},{"key":"2026012113152574700_ehf214638-bib-0036","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023256","article-title":"Newly diagnosed infection after admission for acute heart failure: From the KCHF registry","volume":"10","author":"Seko","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026012113152574700_ehf214638-bib-0037","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.006977","article-title":"Polypharmacy in older adults hospitalized for heart failure","volume":"13","author":"Unlu","year":"2020","journal-title":"Circ Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/2\/950\/64540197\/eschf_11_2_950.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/2\/950\/64540197\/eschf_11_2_950.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:17:29Z","timestamp":1769019449000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/2\/950\/8271308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1,16]]},"published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14638","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,1,16]]},"assertion":[{"value":"2023-07-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}